Why the study?
Patient-reported outcomes are valuable measures for routine clinical care of people with multiple sclerosis.
Do patient-reported outcomes predict future disability worsening in people with multiple sclerosis treated with interferon-β-1a?
Do patient-reported outcomes predict future disability worsening in people with multiple sclerosis treated with interferon-β-1a?
Patient-reported outcomes, specifically fatigue and lower limb limitations, are significant predictors of future disability worsening in multiple sclerosis patients.
May aid risk stratification in interferon-treated MS; leaves open prospective validation before guiding care.
Introduction: Patient-reported outcomes (PROs) are valuable measures for routine clinical care of people with multiple sclerosis (pwMS). Materials: 646 pwMS treated with interferon-β-1a (IFN-β-1a) were retrospectively included from the New York State Multiple Sclerosis Consortium. Clinical and PRO data at enrollment and 3 year follow-up were collected. PwMS with stable disease and disability worsening were matched (1:1) based on age, Expanded Disability Status Scale (EDSS) scores and disease duration. Disability worsening was determined based on trial criteria. Results: PwMS with future EDSS worsening had higher baseline and follow-up timed-25-foot walk (6.6 vs 5.5 s; 9.1 vs 5.5 s; p < 0.001) when compared with stable pwMS. Worsening pwMS reported higher baseline difficulties in getting up (odds ratio [OR] = 2.4; p = 0.009), climbing stairs (OR = 1.6; p = 0.024) and standing (OR = 2.2; p < 0.001). Worsening pwMS reported greater lower limb limitations (OR = 2.3; p = 0.004) and fatigue (OR = 1.8; p = 0.002). Conclusion: Higher fatigue and lower limb functional limitations are significant predictors of future disability worsening in pwMS.
No takes yet. Share an insight, caveat, or question.
Vaughn et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: